Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer
Volume: 14, Issue: 4, Pages: 385 - 390
Published: Jan 29, 2020
Abstract
Introduction: ALK rearrangements are present in 2-7% of non-small cell lung cancer (NSCLC) cases, where the EML4-ALK fusion is the most frequent. Rearrangement of ALK with other fusion partners occurs only in ≈5% of NSCLC ALK-positive. These patients have benefited from ALK inhibitors, and currently, there are three generations of drugs as the standard of care. The first-generation ALK inhibitor crizotinib is approved in the front-line setting...
Paper Details
Title
Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer
Published Date
Jan 29, 2020
Volume
14
Issue
4
Pages
385 - 390
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History